Phase 2B trial of aminopterin in multiagent therapy for children with newly diagnosed acute lymphoblastic leukemia

Cancer Chemotherapy and Pharmacology

Volumn 62, Issue 1, 2008, Pages 65-75

  Cole, Peter D ^a,b,c   Drachtman, Richard A ^a   Masterson, Margaret ^a   Smith, Angela K ^a   Glod, John ^a   Zebala, John A ^d   Lisi, Stacey ^e   Drapala, Drew Anne ^f   Kamen, Barton A ^a,b  

^a ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^c ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^d SYNTRIX BIOSYSTEMS INC   (United States)

^e RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^f Bioarray Solutions   (United States)

Author keywords

Acute lymphoblastic leukemia; Aminopterin; Antifolate; Methotrexate; Therapeutic trial

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE AMINOTRANSFERASE; AMINOPTERIN; ASPARAGINASE; ASPARTATE AMINOTRANSFERASE; CREATININE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DEXAMETHASONE; FOLIC ACID ANTAGONIST; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHIONINE SYNTHASE REDUCTASE; METHOTREXATE; TIOGUANINE; VINCRISTINE;

ABDOMINAL DISCOMFORT; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE OTITIS MEDIA; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; AVASCULAR NECROSIS; B CELL LEUKEMIA; BACTEREMIA; BLOOD TOXICITY; BONE NECROSIS; BONE PAIN; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COXALGIA; CRANIAL NERVE PARALYSIS; CREATININE BLOOD LEVEL; DEHYDRATION; DRUG EFFICACY; DRUG OVERDOSE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DYSARTHRIA; ERYTHRODERMA; FEVER; FOLLOW UP; GENETIC POLYMORPHISM; HEADACHE; HEMIPLEGIA; HEMOGLOBIN BLOOD LEVEL; HERPES ZOSTER; HIGH RISK PATIENT; HUMAN; KNEE PAIN; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LEUKOCYTE COUNT; LIMB PAIN; LIVER FUNCTION TEST; LIVER TOXICITY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPHIL COUNT; PANCREATITIS; PANCYTOPENIA; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SIDE EFFECT; SINUSITIS; STOMATITIS; SYNCOPE; SYSTEMIC THERAPY; THROMBOCYTE COUNT; UREA NITROGEN BLOOD LEVEL; URINARY TRACT INFECTION; VOMITING; WILD TYPE;

ADOLESCENT; AMINOPTERIN; ANTIDOTES; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE DISEASES; CHILD; CHILD, PRESCHOOL; ERYTHROCYTES; FEMALE; FEVER; FOLIC ACID ANTAGONISTS; GASTROINTESTINAL DISEASES; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; NEUROTOXICITY SYNDROMES; OVERDOSE; PILOT PROJECTS; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; TREATMENT OUTCOME;

EID: 42149089308     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0576-7     Document Type: Article

References (58)

1. Asselin BL, Shuster J, Amylon MD, Halperin R, Lipshultz S, Camitta B (2001) Improved event-free survival (EFS) with high dose methotrexate (HDM) in T-cell lymphoblastic leukemia (T-ALL) and Advanced lymphoblastic lymphoma (T-NHL): a Pediatric Oncology Group (POG) Study [Abstract 1464]. Proceedings of the American Society of Clinical Oncology 20
2. Bettachi CJ, Kamen BA, Cush JJ (1999) Post-methotrexate (MTX) CNS toxicity: symptom reduction with dextromethorphan. Arthritis Rheum 42:S236
3. Bleyer AW (1977) Clinical pharmacology of intrathecal methotrexate. II. An improved dosage regimen derived from age-related pharmacokinetics. Cancer Treat Rep 61:1419-1425
4. Capizzi RL (1981) Asparaginase-methotrexate in combination chemotherapy: schedule-dependent differential effects on normal versus neoplastic cells. Cancer Treat Rep 65(Suppl 4):115-121
5. Cole PD, Drachtman RA, Smith AK, Cate S, Larson RA, Hawkins DS, Holcenberg J, Kelly K, Kamen BA (2005) Phase II trial of oral aminopterin for adults and children with refractory acute leukemia. Clin Cancer Res 11:8089-8096
6. Cole PD, Zebala JA, Alcaraz MJ, Smith AK, Tan J, Kamen BA (2006) Pharmacodynamic properties of methotrexate and aminotrexate during weekly therapy. Cancer Chemother Pharmacol 57: 826-834, Epub 2005 Sep 17
7. Costea I, Moghrabi A, Laverdiere C, Graziani A, Krajinovic M (2006) Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 91:1113-1116
8. Dacie JV, Dresner E, Mollin DL, White JC (1950) Aminopterin in the treatment of acute leukemia. Br Med J 1:1447-1457
9. Dameshek W, Freedman MH, Steinberg L (1950) Folic acid antagonists in the treatment of acute and subacute leukemia. Blood 5:898-915
10. Dervieux T, Furst D, Orentas Lein D, Capps R, Smith K, Caldwell J, Kremer J (2005) Pharmacogenetic and metabolite measurements are associated with clinical status in rheumatoid arthritis patients treated with methotrexate: results of a multicentred cross sectional observational study. Ann Rheum Dis: ard.2004.033399
11. Drachtman RA, Cole PD, Golden CB, James SJ, Melnyk S, Aisner J, Kamen BA (2002) Dextromethorphan is effective in the treatment of subacute methotrexate neurotoxicity. Pediatr Hematol Oncol 19:319-327
12. Farber S, Diamond L, Mercer RD, Sylvester RF Jr, Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Eng J Med 238:787
13. Farrow AC, Buchanan GR, Zwiener RJ, Bowman WP, Winick NJ (1997) Serum aminotransferase elevation during and following treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 15:1560-1506
14. George S, Cichowicz DJ, Shane B (1987) Mammalian folylpoly-gamma- glutamate synthetase. 3. Specificity for folate analogues. Biochemistry 26:522-529
15. Goldberg JM, Silverman LB, Levy DE, Dalton VK, Gelber RD, Lehmann L, Cohen HJ, Sallan SE, Asselin BL (2003) Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 21:3616-3622
16. Goldin A, Venditti JM, Humphreys SR, Dennis D, Mantel N (1955) A quantitative comparison of the antileukemic effectiveness of two folic acid antagonists in mice. J Natl Cancer Inst 15:1657-1664
17. Graham M, Winick N, Camitta B, Kamen BA (1992) Equivalence of methotrexate concentration in erythrocytes between IV and oral dosing regimens. Cancer Res Therapy Control 3:53-55
18. Haghbin M, Zuelzer WW (1965) A long-term study of cerebrospinal leukemia. J Pediatr 67:23-28
19. Hendel J, Nyfors A (1984) Pharmacokinetics of methotrexate in erythrocytes in psoriasis. Eur J Clin Pharmacol 27:607-610
20. Jacques PF, Bostom AG, Williams RR, Ellison RC, Eckfeldt JH, Rosenberg IH, Selhub J, Rozen R (1996) Relation between folate status, a common mutation in methylenetetrahydrofolate reductase, and plasma homocysteine concentrations. Circulation 93:7-9
21. Jacques PF, Selhub J, Bostom AG, Wilson PW, Rosenberg IH (1999) The effect of folic acid fortification on plasma folate and total homocysteine concentrations. N Eng J Med 340:1449-1454
22. Jaffe N, Takaue Y, Anzai T, Robertson R (1985) Transient neurologic disturbances induced by high-dose methotrexate treatment. Cancer 56:1356-1360
23. Kearney PJ, Light PA, Preece A, Mott MG (1979) Unpredictable serum levels after oral methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 3:117-120
24. Kluijtmans LAJ, Young IS, Boreham CA, Murray L, McMaster D, McNulty H, Strain JJ, McPartlin J, Scott JM, Whitehead AS (2003) Genetic and nutritional factors contributing to hyperhomocysteinemia in young adults. Blood 101:2483-2488
25. Krajinovic M, Lemieux-Blanchard E, Chiasson S, Primeau M, Costea I, Moghrabi A (2004) Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 4:66-72
26. Krug LM, Ng KK, Kris MG, Miller VA, Tong W, Heelan RT, Leon L, Leung D, Kelly J, Grant SC, Sirotnak FM (2000) Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate. Clin Cancer Res 6:3493-3498
27. Kuehl M, Brixner DI, Broom AD, Avery TL, Blakley RL (1988) Cytotoxicity, uptake, polyglutamate formation, and antileukemic effects of 8-deaza analogues of methotrexate and aminopterin in mice. Cancer Res 48:1481-1488
28. Mahoney DH Jr, Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, Camitta B (1998) Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-a Pediatric Oncology Group study. J Clin Oncol 16:1712-1722
29. Mahoney DH Jr, Shuster J, Nitschke R, Lauer SJ, Winick N, Steuber CP, Camitta B (1998) Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol 16:246-254
30. Mantadakis E, Smith AK, Hynan L, Winick NJ, Kamen BA (2002) Methotrexate polyglutamation may lack prognostic significance in children with BCP-ALL treated with intensive oral methotrexate. J Pediatr Hematol Oncol 24:636-642
31. Mattano LA Jr, Sather HN, Trigg ME, Nachman JB (2000) Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group. J Clin Oncol 18:3262-3272
32. Meyer LM, Fink H, Sawitsky A, Rowen M, Ritz ND (1949) Aminopterin (a folic acid antagonist) in the treatment of leukemia. Am J Clin Pathol 19:119-126
33. Mills SD, Stickney JM, Hadedorn AB (1950) Observations on acute leukemia in children treated with 4-aminopteroylglutamic acid. Pediatrics 5:52-56
34. Moran RG, Colman PD, Rosowsky A, Forsch RA, Chan KK (1985) Structural features of 4-amino antifolates required for substrate activity with mammalian folylpolyglutamate synthetase. Mol Pharmacol 27:156-166
35. Nachman J (2005) Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia. Br J Haematol 130:166-173
36. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, Lukens JN, Wolff L, Uckun FM, Gaynon PS (1998) Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Eng J Med 338:1663-1671
37. O'Connor O (2006) Pralatrexate: an emerging new agent with activity in T-cell lymphomas. Curr Opin Oncol 18:591-597
38. Piper JR, Montgomery JA (1974) A convenient synthesis of aminopterin and homologues via 6-(bromethyl)-2,4-disminopteridine hydrobromide. J Heterocycl Chem 11:279-280
39. Quinn CT, Kamen BA (1996) A biochemical perspective of methotrexate neurotoxicity with insight on nonfolate rescue modalities. J Invest Med 44:522-530
40. Ratliff AF, Wilson J, Hum M, Marling-Cason M, Rose K, Winick N, Kamen BA (1998) Phase I and pharmacokinetic trial of aminopterin in patients with refractory malignancies. J Clin Oncol 16:1458-1464
41. Reddick WE, Glass JO, Helton KJ, Langston JW, Xiong X, Wu S, Pui C-H (2005) Prevalence of leukoencephalopathy in children treated for acute lymphoblastic leukemia with high-dose methotrexate. Am J Neuroradiol 26:1263-1269
42. Renard D, Westhovens R, Vandenbussche E, Vandenberghe R (2004) Reversible posterior leucoencephalopathy during oral treatment with methotrexate. J Neurol 251:226-228
43. Rieselbach RE, Morse EE, Rall DP, Frei E, Freireich EJ (1963) Intrathecal aminopterin therapy of meninigeal leukemia. Arch Intern Med 111:620-630
44. Robien K, Boynton A, Ulrich CM (2005) Pharmacogenetics of folate-related drug targets in cancer treatment. Pharmacogenomics 6:673-689
45. Rocha JC, Cheng C, Liu W, Kishi S, Das S, Cook EH, Sandlund JT, Rubnitz J, Ribeiro R, Campana D, Pui CH, Evans WE, Relling MV (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105:4752-4758
46. Rubnitz JE, Lensing S, Zhou Y, Sandlund JT, Razzouk BI, Ribeiro RC, Pui CH (2004) Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer 101:1677-1684
47. Schoenbach EB, Colsky J, Greenspan EM (1952) Observations on the effects of the folic acid antagonists, aminopterin and amethopterin, in patients with advanced neoplasms. Cancer 5:1201-1220
48. Schroder H (1990) In vivo methotrexate kinetics and metabolism in human hematopoietic cells. Clinical significance of methotrexate concentrations in erythrocytes. Dan Med Bull 37:22-40
49. Sirotnak FM, DeGraw JI, Colwell WT, Piper JR (1998) A new analogue of 10-deazaaminopterin with markedly enhanced curative effects against human tumor xenografts in mice. Cancer Chemother Pharmacol 42:313-318
50. Sirotnak FM, DeGraw JI, Schmid FA, Goutas LJ, Moccio DM (1984) New folate analogs of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother Pharmacol 12:26-30
51. Sirotnak FM, Donsbach RC (1972) Comparitive studies on the transport of aminopterin, methotrexate, and methasquin by the L1210 leukemia cell. Cancer Res 32:2120-2126
52. Sirotnak FM, Donsbach RC (1975) A basis for the difference in toxicity of methotrexate, aminopterin and methasquin in mice. Biochem Pharmacol 24:156-158
53. Smith A, Hum M, Winick NJ, Kamen BA (1996) A case for the use of aminopterin in treatment of patients with leukemia based on metabolic studies of blasts in vitro. Clin Cancer Res 2:69-73
54. Strauss AJ, Su JT, Dalton VM, Gelber RD, Sallan SE, Silverman LB (2001) Bony morbidity in children treated for acute lymphoblastic leukemia. J Clin Oncol 19:3066-3072
55. Ulrich CM, Robien K, Sparks R (2002) Pharmacogenetics and folate metabolism-a promising direction. Pharmacogenomics 3:299-313
56. Vezmar S, Becker A, Bode U, Jaehde U (2003) Biochemical and clinical aspects of methotrexate neurotoxicity. Chemotherapy 49:92-104
57. Winick NJ, Bowman WP, Kamen BA, Roach ES, Rollins N, Jacaruso D, Buchanan GR (1992) Unexpected acute neurologic toxicity in the treatment of children with acute lymphoblastic leukemia. J Natl Cancer Inst 84:252-256
58. Winick N, Shuster JJ, Bowman WP, Borowitz M, Farrow A, Jacaruso D, Buchanan GR, Kamen BA (1996) Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clin Oncol 14:2803-2811